Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL261462 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL261880 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL262153 | 0.95 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL261702 | 0.95 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL261703 | 0.95 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL261214 | 0.92 | S1PR1 (0.91) | S1PR1S1PR3 | |
| SCHEMBL262295 | 0.92 | S1PR1 (0.91) | S1PR1S1PR3 | |
| SCHEMBL261215 | 0.92 | S1PR1 (0.91) | S1PR1S1PR3 | |
| SCHEMBL263222 | 0.90 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL261548 | 0.90 | S1PR1 (1.00) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069322-B1 | THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-09-12 | — | — | EP | claimed |
| US-8133910-B2 | Thiophene derivatives as S1P1/EDGE1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-13 | — | — | US | claimed |
| US-20100048648-A1 | Thiophene derivatives as S1P1/EDGE1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-25 | — | — | US | claimed |
| EP-2069322-A2 | THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | claimed |
| WO-2008029306-A2 | THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | claimed |
| EP-2069322-B1 | THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-09-12 | — | — | EP | disclosed |
| US-8133910-B2 | Thiophene derivatives as S1P1/EDGE1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-13 | — | — | US | disclosed |
| US-20100048648-A1 | Thiophene derivatives as S1P1/EDGE1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-25 | — | — | US | disclosed |
| EP-2069322-A2 | THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008029306-A2 | THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048648-A1 | Thiophene derivatives as S1P1/EDGE1 receptor agonists | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.